Case Study: Targeting Reversal Therapy in Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension (PAH) is characterized by increased blood pressure in the arteries of lungs, causing dizziness, shortness of breath and can lead to heart failure.
PAH is an orphan disease that the CorDynamics team has studied extensively including generating terminal assessments of pulmonary arterial pressure to provide demonstration of efficacy.
In addition, measuring pulmonary artery pressure via single or dual channel telemetry to deliver daily readings of pulmonary artery pressures. These interim measurements of the PAH temporal course has been critical for clients interested in timing the initiation of reversal therapy.
Our daily data demonstrate that the variability associated with the model is small, even over six weeks of hypoxia. Animals progressed through development of PAH in a similar linear fashion. After six weeks in hypoxia, systolic pulmonary pressures increased greater than 400% versus baseline. In addition, right ventricular hypertrophy was robust. The low variability helps in the assessment of test article efficacy – and allows for better distribution of dose levels without having to add inordinate experimental numbers.
Related Posts via Categories
- Pulmonary Arterial Hypertension,
- Pulmonary Arterial Hypertension Drug Discovery,